- Home
- YOUL vs SPRO Comparison
YOUL vs SPRO Comparison
Compare YOUL & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YOUL | SPRO |
|---|---|---|
| Founded | N/A | 2013 |
| Country | China | United States |
| Employees | N/A | 32 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.2M | 124.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | YOUL | SPRO |
|---|---|---|
| Price | $1.13 | $2.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 60.6K | ★ 337.8K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $47,977,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.78 | $0.51 |
| 52 Week High | $4.40 | $3.09 |
Technical Indicators
Market Signals| Indicator | YOUL | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 36.65 |
| Support Level | $1.09 | $2.15 |
| Resistance Level | $1.95 | $2.44 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 23.08 | 2.20 |
Price Performance
Historical ComparisonAbout YOUL Youlife Group Inc. American Depositary Shares
Youlife Group Inc is a blue-collar lifetime service provider with a nationwide network of 25 vocational schools under school management model and 25 curriculum development projects, covering a total of 37 cities or counties under 16 provinces of China.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.